Contra-indicated for pregnant females; patients who have had anaphylactic or anaphylactoid reactions to neomycin; febrile respiratory illness or other active febrile infection; patients receiving immunosuppressive therapy or with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems; primary and acquired immunodeficiency states, or individuals with a family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.